RYTM
Rhythm Pharmaceuticals, Inc.−$7.00 (7.49%) At close $86.44 · Today
☾After Hours +$1.02 (1.18%) Nov 3, 7:59 PM ET
About RYTM
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Company
- Headquarters
- Boston, MA
- Employees
- 414 (2026)
- Listed
- Oct 5, 2017
- Exchange
- Nasdaq
- Website
- rhythmtx.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #44 of 430
- P/B #14 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T-0.11%
- JNJJohnson & Johnson$640.8B-1.62%
- ABBVAbbVie Inc$505.4B-0.98%
- MRKMerck & Co Inc$356.9B-2.49%
- NVSNovartis AG$300.8B-1.40%
Financial summary
Related companies
About
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.